Stay updated with breaking news from Mike biega. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 MillionRetinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Rel...
11.02.2022 - LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering ...
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer - read this article along with other careers information, tips and advice on BioSpace
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics Appoints Si - GuruFocus.com gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share: DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,020,393 entitled, "Methods of Treating Disease with Levoketoconazole" which covers a method of treating Cushing's syndrome patients with RECORLEV ® (levoketoconazole) who also take metformin for Type 2 diabetes. The term of the U.S. patent will expire on March 2, 2040. This will be the third patent issued in the U.S. relating to RECORLEV. The first, U.S. Patent No. 9,198,906, covers methods of reducing C-reactive protein levels and systemic inflammation through administration of a once-daily dose of RECORLEV and will expire on December 29, 2030. The second, U.S. patent No. 9,918,984, covers methods of treating Cushing's syndrome with levoketoconazole and will expire on January 10, 2026.